Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2010

View Archived Issues

Banyu and Merck & Co. claim novel Akt1 inhibitors for cancer therapy

Everolimus effective in patients with metastatic pancreatic neuroendocrine tumors

Synta Pharmaceuticals discloses Hsp90 inhibitors for the treatment of cancer

TRPA1 antagonists described by Janssen for the treatment of pain

Roche describes liver X receptor agonists for the treatment of atherosclerosis

Novartis claims ENaC blockers for the treatment of cystic fibrosis

Oramed completes patient enrollment in pivotal phase IIb trial of ORMD-0801

Orexin receptor antagonists for treating sleep disorders claimed by Actelion

Cobalamin oral insulin shows promise in preclinical trials

Michael J. Fox Foundation awards grant for neuroprotective therapies for PD

Halozyme Therapeutics enters research alliance with BioAtla

Novel hybrid potentiator-corrector molecule for the treatment of CF disclosed

Generation of tumor-targeted nanoparticles for potential clinical use

Sorafenib shows low activity in phase II trial in advanced biliary tract carcinoma

Dal-OUTCOMES trial to evaluate dalcetrapib in acute coronary syndrome

NS3/4A protease inhibitors reported by BMS for HCV infection

Shionogi's Cymbalta approved for depression in Japan

Schering-Plough obtains Japanese approval for Bridion

Wyeth launches BeneFIX for hemophilia B

ImmunoCellular's ICT-107 vaccine specifically targets cancer stem cells

Bharat Biotech initiates phase I clinical trial of HN-VAC H1N1 vaccine

Lexicon's LX-4211 demonstrates improvements in phase II trial in type 2 diabetes

New dosage form of Mitsubishi Tanabe's neuroprotectant Radicut approved

BTG initiates phase IIa study of Pleneva in multiple sclerosis

4SC commences dosing in a first-in-man phase I study of 4SC-203

Mitsubishi Tanabe's Remicade approved for the additional indication of psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...